MedTrace Logo

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

NCT02422381 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-02-18

Study results available
· View outcomes & findings →

Summary

This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine. The study will also try to identify the best dose of MK-3475 to give in combination with gemcitabine.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

MK-3475

Investigational drug.

DRUG

Gemcitabine

Standard care drug.

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Providence Cancer Center, Earle A. Chiles Research Institute

    collaborator OTHER

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Rachel Sanborn, MD · Providence Health & Services

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-20
Primary Completion
2019-01-09
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02422381 on ClinicalTrials.gov